Article

A phase I study of a dual PI3-Kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

2020-09-09

Abstract excerpt

<title>Abstract</title> <p><bold>Background </bold>Combined inhibition of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) complexes may be an efficient treatment for acute leukemia. The primary objective of this phase I single center open label study was to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the dual pan-class I PI3K and mTOR inhibi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: caab7d6e-7b34-5ded-bda7-84564d2974ec
DOI: 10.21203/rs.2.20890/v4

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A phase I study of a dual PI3-Kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemiaDOI 10.21203/rs.2.20890/v4Read

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemiaSemantic proximity Read

Outlook on PI3K/AKT/mTOR inhibition in acute leukemiaSemantic proximity Read

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaSemantic proximity Read

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.Semantic proximity Read

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screenSemantic proximity Read

Targeting the mTOR Pathway in LeukemiaSemantic proximity Read

Anti-leukemia effects of Omipalisib in Acute Myeloid Leukemia: inhibition of PI3K-AKT-mTOR signaling and suppression of Mitochondrial BiogenesisSemantic proximity Read

Targeting mTOR in Acute Lymphoblastic LeukemiaSemantic proximity Read

Antileukaemic effect of <scp>PI</scp>3<scp>K</scp>‐m<scp>TOR</scp> inhibitors in acute myeloid leukaemia‐gene expression profiles reveal <scp>CDC</scp>25<scp>B</scp> expression as determinate of pharmacological effectSemantic proximity Read

Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist VenetoclaxSemantic proximity Read

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.Semantic proximity Read

Anlotinib Exerts Potent Antileukemic Activities in B-Cell Acute Lymphoblastic Leukemia Via Attenuation of PI3K/AKT/mTOR Signaling CascadeSemantic proximity Read